Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01639625

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Squamous Cell Carcinoma of the Cervix Clinical Trial

Official title:
Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation

Clinical Trial Summary

They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01639625
Study type Interventional
Source Laboratorio Elea S.A.C.I.F. y A.
Contact
Status Completed
Phase Phase 2
Start date May 2011
Completion date January 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03894618 - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Phase 1
Terminated NCT02042885 - A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer Phase 1/Phase 2
Active, not recruiting NCT03357757 - Avelumab With Valproic Acid in Virus-associated Cancer Phase 2
Recruiting NCT03221400 - PEN-866 in Patients With Advanced Solid Malignancies Phase 1/Phase 2